Conclusion
Breast implants are among the most thoroughly studied medical devices. Although systemic complications are sensationalized in the media, local complications are much more prevalent. The primary care provider is often the first clinician to identify complications of breast augmentation, especially beyond the one-year postprocedure period. Thus, primary care providers must be aware of the local complications that may arise.
Anaplastic large-cell lymphoma is being studied as a possible complication of breast augmentation. Clinicians should be alert to possible development of a seroma six months or longer after an augmentation procedure.
References
1.
13.8 million cosmetic plastic surgery procedures performed in 2011 [press release]. Arlington Heights, IL: American Society of Plastic Surgeons; February 9, 2012.
2. FDA. Medical devices: risks of breast implants (2013). www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/Breastimplants/ucm064106.htm. Accessed May 14, 2013.
3. Juanpere S, Perez E, Huc O, et al. Imaging of breast implants: a pictorial review. Insights Imaging. 2011;2:653-690.
4. Adams WP Jr. Capsular contracture: what is it? What causes it? How can it be prevented and managed? Clin Plast Surg. 2009;36:119-126.
5. El-Sheikh Y, Tutino R, Knight C, et al. Incidence of capsular contracture in silicone versus saline cosmetic augmentation mammoplasty: a meta-analysis. Can J Plast Surg. 2008;16:211-215.
6. Blount AL, Martin MD, Lineberry KD, et al. Capsular contracture rate in a low-risk population after primary augmentation mammaplasty. Aesthet Surg J. 2013;33:516-521.
7. Schaub TA, Ahmad J, Rohrich RJ. Capsular contracture with breast implants in the cosmetic patient: saline versus silicone—a systematic review of the literature. Plast Reconstr Surg. 2010;126:2140-2149.
8. Hvilsom GB, Hölmich LR, Henriksen TF, et al. Local complications after cosmetic breast augmentation: results from the Danish Registry for Plastic Surgery of the Breast. Plast Reconstr Surg. 2009;124:919-925.
9. Thompson PA, Lade S, Webster H, et al. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Haematologica. 2010;95:1977-1979.
10. Brody GS, Deapen D, Gill P, et al. T-cell non-Hodgkin’s anaplastic lymphoma associated with one style of breast implants. Presented at: American Society of Plastic Surgeons Annual Conference; March 20-23, 2010; San Antonio, Texas. Abstract 42.
11. FDA, Center for Devices and Radiological Health. Anaplastic large cell lymphoma (ALCL) in women with breast implants: preliminary FDA findings and analyses (2011). www.fda.gov/MedicalDevices/ProductsandMedical Procedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm. Accessed May 14, 2013.
12. Carty MJ, Pribaz JJ, Antin JH, et al. A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg. 2011;128:112e-118e.
13. Kim B, Roth C, Young VL, et al. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg. 2011;128:629-639.
14. Kim B, Roth CP, Chung KC, et al. Are breast implants linked to a rare form of lymphoma? www.rand.org/pubs/research_briefs/RB9584.html. Accessed May 14, 2013.
15. Silicone gel-filled breast implants approved. FDA Consum. 2007;41:8-9.
16. Johnson JA; Congressional Research Service. FDA regulation of medical devices (2012). www.fas.org/sgp/crs/misc/R42130.pdf. Accessed May 14, 2013.
17. FDA. Update on the safety of silicone gel–filled breast implants (2011). www.fda.gov/downloads/medicaldevices/productsandmedicalprocedures/implantsandprosthetics/breastimplants/UCM260090.pdf. Accessed May 14, 2013.
18. Bondurant S, Ernster V, Herdman R, eds; Committee on the Safety of Silicone Breast Implants, Division of Health Promotion and Disease Prevention, Institute of Medicine. Washington, DC: National Academy Press; 1999.
19. Spear SL, Hedén P. Allergan’s silicone gel breast implants. Expert Rev Med Devices. 2007;4:699-708.
20. Cunningham B. The Mentor core study on silicone MemoryGel breast implants. Plast Reconstr Surg. 2007;120(7 suppl 1):19S-32S.
21. Spear SL, Baker JL Jr. Classification of capsular contracture after prosthetic breast reconstruction. Plast Reconstr Surg. 1995;96:1119-1123.
22. Schreml S, Heine N, Eisenmann-Klein M, Pranti L. Bacterial colonization is of major relevance for high-grade capsular contracture after augmentation mammaplasty. Ann Plast Surg. 2007;59:126-130.
23. Siggelkow W, Faridi A, Spiritus K, et al. Histological analysis of silicone breast implant capsules and correlation with capsular contracture. Biomaterials. 2003;24:1101-1109.
24. Henriksen TF, Fryzek JP, Hölmich LR, et al. Surgical intervention and capsular contracture after breast augmentation: a prospective study of risk factors. Ann Plast Surg. 2005;54:343-351.
25. Amano Y, Aoki R, Kumita S, Kumazaki T. Silicone-selective multishot echo-planar imaging for rapid MRI survey of breast implants. Eur Radiol. 2007;17:1875-1878.
26. Maxwell GP, Van Natta BW, Murphy DK, et al. Natrelle style 410 form-stable silicone breast implants: core study results at 6 years. Aesthet Surg J. 2012;32:709-717.
27. Stevens WG, Harrington J, Alizadeh K, et al. Five-year follow-up data from the US clinical trial for Sientra’s U.S. Food and Drug Administration-approved Silimed® brand round and shaped implants with high-strength silicone gel. Plast Reconstr Surg. 2012;130:973-981.
28. Hold PM, Alam S, Pilbrow WJ, et al. How should we investigate breast implant rupture? Breast J. 2012;18:253-256.
29. Everson LI, Parantainen H, Detlie T, et al. Diagnosis of breast implant rupture: imaging findings and relative efficacies of imaging techniques. AJR Am J Roentgenol. 1994;163:57-60.
30. Hölmich LR, Vejborg IM, Conrad C, et al. Untreated silicone breast implant rupture. Plast Reconstr Surg. 2004;114:204-214.
31. Dowden RV, Reisman NR. Breast implant overfill, optimal fill, and the standard of care. Plast Reconstr Surg. 1999;104:1185-1186.
32. Spear SL, Sinkin JC, Al-Attar A. Porcine acellular dermal matrix (Strattice™) in primary and revision cosmetic breast surgery. Plast Reconstr Surg. 2013;131:1140-1148.
33. Shestak KC. Acellular dermal matrix inlays to correct significant implant malposition in patients with compromised local tissues. Aesthet Surg J. 2011;31(7 suppl):85S-94S.
34. Spear SL, Bogue DP, Thomassen JM. Synmastia after breast augmentation. Plast Reconstr Surg. 2006;118(7 suppl):168S-171S.
35. Selvaggi G, Giordano S, Ishak L. Synmastia: prevention and correction. Ann Plast Surg. 2010;65:455-461.
36. Coscia J, Lance S, Wong M, Garcia J. Mondor’s thrombophlebitis 13 years after breast augmentation. Ann Plast Surg. 2012;68:336-337.
37. Dudrap E, Milliez PY, Auquit-Auckbur I, Bony-Rerolle S. Mondor’s disease and breast plastic surgery [in French]. Ann Chir Plast Esthet. 2010; 55:233-237.